Skip to main content

REVIEW article

Front. Immunol.
Sec. Molecular Innate Immunity
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1372009
This article is part of the Research Topic The role of the immune system in eosinophilic diseases View all 7 articles

Balancing immune responses: regulatory cells in eosinophilic gastrointestinal disorders (EGIDs)

Provisionally accepted
Nassim kheshtchin Nassim kheshtchin 1Zahra Kanannejad Zahra Kanannejad 2*Zahra Ghahramani Zahra Ghahramani 3Hossein Esmaeilzadeh Hossein Esmaeilzadeh 4Najmeh Sepahi Najmeh Sepahi 2
  • 1 Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Fars, Iran
  • 2 Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • 3 Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Fars, Iran
  • 4 department of allergy and clinical immunology, shiraz university of medical sciences, shiraz, iran, Shiraz, Fars, Iran

The final, formatted version of the article will be published soon.

    Eosinophilic gastrointestinal disorders (EGIDs) are a group of conditions characterized by an abnormal accumulation of eosinophils in the gastrointestinal tract, leading to inflammation and tissue damage. Regulatory cells are a subset of immune cells that are crucial in maintaining the balance of the immune system and preventing the occurrence of autoimmune diseases. In EGIDs, regulatory cells are believed to play a key role in controlling the immune response and overseeing the growth and activation of eosinophils in the gastrointestinal tract. There is evidence indicating that regulatory T cells (Tregs) and regulatory eosinophils may play a role in suppressing the inflammatory response in EGIDs. Regulatory eosinophils are a subgroup of eosinophils that possess an anti-inflammatory role. Recent studies have shown that enhancing the number or effectiveness of regulatory eosinophils can reduce the severity of EGIDs. Regulatory eosinophils dampen inflammation through their regulatory mediators, such as galectin-10 and growth factor beta (TGF-β), which promote Treg expansion and inhibit effector T cell function. Further research on regulatory cells in EGIDs may have significant implications for the advancement of novel therapies for these uncommon and intricate disorders. The aim of this review is to provide complete view of the immune responses connected to EGIDs, examine the regulatory cells that control these responses, and evaluate their potential as therapeutic targets for EGID treatment.

    Keywords: Eosinophilic gastrointestinal disorders, Inflammation, Immune System, Regulatory Eosinophil, regulatory T-cells

    Received: 17 Jan 2024; Accepted: 16 Jul 2024.

    Copyright: © 2024 kheshtchin, Kanannejad, Ghahramani, Esmaeilzadeh and Sepahi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Zahra Kanannejad, Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.